A new Israeli study appears to confirm that people with natural immunity have better protection against the NEW DELTA VARIANT than people who have been fully vaccinated.
The team of researchers, from Maccabi Healthcare and Tel Aviv University, published their study earlier this week to medRxiv.org.
‘This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, ‘ the team of researchers wrote.
Not even a little bit better. People who have received both doses of the Pfizer vaccine are 13 TIMES more likely to develop a breakthrough infection and are even at a “greater risk for Covid-19 hospitalizations.”
The researchers conducted a large study on 800,000 people divided into three groups. People who had received one or two doses of the Pfizer-BioNTech COVID-19 vaccine were compared to unvaccinated individuals who had natural immunity because they had already recovered from the virus.
SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant (P<0.001) for symptomatic disease as well.
When allowing the infection to occur at any time before vaccination (from March 2020 to February 2021), evidence of waning natural immunity was demonstrated, though SARS-CoV-2 naïve vaccinees had a 5.96-fold (95% CI, 4.85 to 7.33) increased risk for breakthrough infection and a 7.13-fold (95% CI, 5.51 to 9.21) increased risk for symptomatic disease. SARS-CoV-2-naïve vaccinees were also at a greater risk for COVID-19-related-hospitalizations compared to those that were previously infected.
MOST IMPORTANTLY, the study discovered that three months after a second dose, the risk of contracting Covid was 13.06 times higher among those who had been vaccinated, and they were 27 TIMES more likely to experience symptoms.
After adjusting for comorbidities, we found a 27.02-fold risk (95% CI, 12.7 to 57.5) for symptomatic breakthrough infection as opposed to symptomatic reinfection (P<0.001) (Table 2b). None of the covariates were significant, except for age ≥60 years.
According to these highly credible researchers, who conducted a large study on hundreds of thousands of people, the Pfizer-BioNTech vaccine will not only make people more likely to catch new variants, but they will also be more affected by symptoms and more likely to end up in the hospital.
This new data adds to a growing body of evidence demonstrating the experimental jab’s ineffectiveness in preventing the spread of the virus. Even before this latest study, some researchers had discovered that the vaccinated spread the virus just as much, if not more, than the unvaccinated.